AMENDMENTS

In the Claims:

Please amend claims 1-2 and 5 as follows:

1. (Twice amended) An isolated recombinant, replication-deficient adenoviral vector, said vector comprising:

an adenoviral sequence from which the E1A/E1B genes have been deleted; a transgene coding for a stress related factor which is a heat shock protein; and a promoter operably linked to said transgene, wherein expression of the transgene is controlled by said promoter.

- 2. (Once amended) The vector of claim 1, wherein said stress related factor is selected from the group consisting of HSP70i, HSP27, HSP40, and HSP60.
- 5. (Once amended) A method of producing a recombinant replication-deficient adenoviral vector comprising a transgene coding for a stress related factor, comprising the steps of:

co-transfecting a plasmid comprising a transgene coding for a stress related factor, a promoter and a polylinker flanked by adenoviral sequences of the left end of the human adenovirus 5 genome from which the E1A/E1B genes have been deleted into a mammalian cell transformed with E1A/E1B genes, with a plasmid which contains the entire human adenoviral 5 genome, and an additional insert making the plasmid too large to be encapsulated, whereby rescue recombination takes place between the transgene-inserted plasmid and the plasmid having the entire adenoviral genome so as to create a recombinant genome containing the transgene without the E1A/E1B genes, said recombinant genome being sufficiently small to be encapsulated;

identifying cells comprising recombinant vectors in cell cultures; propagating the resulting recombinant vectors in mammalian cells transformed with the

E1A/ElB genes; and

purifying the propagated recombinant vectors.

- 21. (New) A method of producing a recombinant replication-deficient adenoviral vector comprising a transgene coding for a stress related factor, comprising the step of propagating a replication-deficient adenoviral vector, wherein said adenoviral vector comprises a transgene coding for a stress related factor, a promoter operably linked to said transgene, and lacks E1A/E1B genes, in a mammalian cell transformed with adenovirus E1A/E1B genes.
- 22. (New) The method of claim 21 further comprising the step of identifying mammalian cells comprising recombinant adenoviral vectors.
- 23. (New) The method of claim 22 further comprising the step of purifying said identified mammalian cells.
- 24. (New) The method of claim 21 wherein said adenoviral vector is a human adenoviral vector.

25. (New) The method of claim 1 wherein said adenoviral vector is a human adenoviral vector.

- 26. (New) A host cell comprising the adenoviral vector of claim 1.
- 27. (New) The host cell of claim 26, which is mammalian.
- 28. (New) A recombinant adenoviral particle comprising the adenoviral vector of claim 1.
 - 29. (New) A composition comprising the adenoviral vector of claim 1.
 - 30. (New) A composition comprising the adenoviral particle of claim 28.

- 31. (New) The composition of claim 29 further comprising a pharmaceutically acceptable carrier.
- 32. (New) The composition of claim 30 further comprising a pharmaceutically acceptable carrier.